Carl Anthony Evans - 01 Feb 2024 Form 4 Insider Report for CNS Pharmaceuticals, Inc. (CNSP)

Reporting relationship: Director
Issuer ticker: CNSP
Reported as of: 01 Feb 2024
Net transaction value: +$10,000
SEC form: 4
Accepted by SEC: 06 Feb 2024, 10:27:56 UTC
Prior SEC filing: 12 Oct 2023
Next SEC filing: 10 Apr 2024
Source filing: View source filing
Reporting owner signature: /s/ Christopher Downs, Attorney-in-fact

Key filing fact

Carl Anthony Evans filed Form 4 for CNS Pharmaceuticals, Inc. (CNSP) on 06 Feb 2024.

Key facts

This page summarizes Carl Anthony Evans's Form 4 filing for CNS Pharmaceuticals, Inc. (CNSP).
3 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 06 Feb 2024, 10:27.

Change

Previous filing in this sequence was filed on 12 Oct 2023.
Current net transaction value: +$10,000.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CNSP transaction

Common stock

Purchase

Transaction value: $10,000
Shares: +33,333
Change %: +26666%
Price: $0.3000
Shares after: 33,458
Date: 01 Feb 2024
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CNSP transaction Derivative

Series A Warrant to purchase common stock

Award

Transaction value
Shares: +33,333
Change %: +73%
Price
Shares after: 78,761
Date: 01 Feb 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 33,333
Exercise price: $0.3000
Footnotes: F1

CNSP transaction Derivative

Series B Warrant to purchase common stock

Award

Transaction value
Shares: +33,333
Change %: +42%
Price
Shares after: 112,094
Date: 01 Feb 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 33,333
Exercise price: $0.3000
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The common stock, Series A warrants and Series B warrants were acquired by the reporting person in a public offering conducted by the Company that was closed on February 1, 2024.